Stocktoria
Cytosorbents Corp CTSO
Cytosorbents Corp financials (annual)
Bars are annual figures from 2016 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $37.1M | $35.6M | $31.1M | $34.7M | $43.2M | $41.0M | $24.9M | $22.5M | $15.2M | $9.5M |
| Gross profit | $26.5M | $24.9M | $22.0M | $20.7M | $32.1M | $30.0M | $17.6M | $15.0M | $9.6M | $5.6M |
| R&D expense | — | — | $15.7M | $15.1M | $16.4M | $8.8M | $12.1M | $7.7M | $3.2M | $4.1M |
| SG&A expense | $35.6M | $33.7M | $38.3M | $34.3M | $35.8M | $28.5M | $22.0M | $20.9M | $14.9M | $11.8M |
| Operating income | -$14.7M | -$16.5M | -$31.9M | -$31.5M | -$22.7M | -$10.4M | -$19.0M | -$15.6M | -$9.8M | -$11.5M |
| Income tax | -$401,000 | -$1.7M | -$813,739 | -$1.1M | -$736,003 | -$1.1M | -$1.1M | -$619,546 | -$676,739 | -$318,550 |
| Net income | -$8.2M | -$20.7M | -$29.2M | -$32.8M | -$24.6M | -$7.8M | -$19.3M | -$17.2M | -$8.5M | -$11.8M |
| EPS (diluted) | $-0.13 | $-0.38 | $-0.65 | $-0.75 | $-0.57 | $-0.20 | $-0.60 | — | — | — |
| Operating cash flow | -$12.4M | -$14.4M | -$21.7M | -$28.2M | -$14.0M | -$5.6M | -$16.8M | -$10.8M | -$6.5M | -$6.7M |
| Free cash flow | -$12.5M | -$14.7M | -$22.2M | -$34.3M | -$17.6M | -$6.3M | -$17.5M | -$11.5M | -$7.5M | -$6.9M |
| Cash & equivalents | $6.2M | $3.3M | $14.1M | $22.1M | $52.1M | $71.4M | $12.2M | $22.4M | $17.3M | $5.2M |
| Inventory | $5.3M | $2.7M | $3.4M | $3.5M | $4.8M | $2.7M | $2.1M | $833,133 | $795,657 | $833,976 |
| Total assets | $44.2M | $47.4M | $53.0M | $63.2M | $89.5M | $90.0M | $27.4M | $34.2M | $24.1M | $9.7M |
| Total liabilities | $38.3M | $36.3M | $29.5M | $27.9M | $26.9M | $10.7M | $24.0M | $17.3M | $13.8M | $8.4M |
| Shareholders' equity | $5.9M | $11.1M | $23.5M | $35.4M | $62.6M | $79.2M | $3.4M | $16.9M | $10.3M | $1.3M |
Growth · year-over-year · Revenue CAGR 16.3%
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue growth | +4.1% | +14.5% | -10.4% | -19.6% | +5.3% | +64.4% | +10.9% | +48.5% | +59.0% | +98.8% |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.